Literature DB >> 6804496

Role of human factor VIII in factor X activation.

M B Hultin.   

Abstract

The cofactor function of human Factor VIII in Factor X activation was investigated by an initial-rate assay of 3H-Factor X activation in the presence of human factor IXa, Ca2+, and either phospholipid or fresh washed human platelets. Purified Factor VIII that has not been activated by thrombin or Factor Xa supports Factor X activation after a lag of several minutes. A specific inhibitor of Factor Xa, which had no inhibitory activity against Factor IXa, markedly prolonged this lag, whereas specific thrombin inhibitors did not prolong the lag. These data support the conclusion that unactivated Factor VIII has no ability to support Factor X activation in a purified system until it is activated by Factor Xa feedback during the lag period. When Factor VIII was optimally preactivated by thrombin, the lag was completely abolished, regardless of the order of addition of the other reactants or the phospholipid source. These data indicate that there is no slow, time-dependent ordering of the reactants at the phospholipid or activated platelet surface if Factor VIII has been preactivated. Unactivated platelets did not support Factor X activation by Factors IXa and VIII. The effect of activated Factor VIII on the kinetics of bovine Factor X activation was primarily to increase the Vmax (54-fold), whereas with human Factor X, Factor VIII both increased the Vmax 56-fold and decreased the Km sixfold to 0.14 microM, similar to the plasma concentration of Factor X. Therefore, a change in the plasma factor X concentration would be expected to have a major effect on the rate of Factor X activation in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804496      PMCID: PMC370149          DOI: 10.1172/jci110534

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin.

Authors:  B Osterud; S I Rapaport; S Schiffman; M M Chong
Journal:  Br J Haematol       Date:  1971-12       Impact factor: 6.998

2.  The mechanism of activation of bovine factor X (Stuart factor) by intrinsic and extrinsic pathways.

Authors:  K Fujikawa; M H Coan; M E Legaz; E W Davie
Journal:  Biochemistry       Date:  1974-12-17       Impact factor: 3.162

3.  Activation of factor X: kinetic properties of the reaction.

Authors:  D P Kosow; B Furie; H Forastieri
Journal:  Thromb Res       Date:  1974-02       Impact factor: 3.944

4.  Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IX.

Authors:  B Osterud; S I Rapaport
Journal:  Biochemistry       Date:  1970-04-14       Impact factor: 3.162

5.  The role of heparin in intrinsic blood coagulation.

Authors:  F A Pitlick; R L Lundblad; E W Davie
Journal:  J Biomed Mater Res       Date:  1969-03

6.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

7.  The activation of factor X evaluated by using synthetic substrates.

Authors:  H Suomela; M Blombäck; B Blombäck
Journal:  Thromb Res       Date:  1977-02       Impact factor: 3.944

8.  Effect of temperature and inhibitors on serotonin-14C release from human platelets.

Authors:  J F Valdorf-Hansen; M B Zucker
Journal:  Am J Physiol       Date:  1971-01

9.  The binding of human and bovine thrombin to human platelets.

Authors:  M A Shuman; D M Tollefsen; P W Majerus
Journal:  Blood       Date:  1976-01       Impact factor: 22.113

10.  Proteolytic activation of protein C from bovine plasma.

Authors:  W Kisiel; L H Ericsson; E W Davie
Journal:  Biochemistry       Date:  1976-11-02       Impact factor: 3.162

View more
  8 in total

1.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  Dissimilar interaction of factor VIII with endothelial cells and lipid vesicles during factor X activation.

Authors:  H J Brinkman; P Koster; K Mertens; J A van Mourik
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

4.  Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott syndrome.

Authors:  S S Ahmad; R Rawala-Sheikh; B Ashby; P N Walsh
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  Intrinsic versus extrinsic coagulation. Kinetic considerations.

Authors:  B J Warn-Cramer; S P Bajaj
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

6.  Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: application to the feedbacks of blood coagulation.

Authors:  E Beltrami; J Jesty
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

7.  Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.

Authors:  A Leyte; K Mertens; B Distel; R F Evers; M J De Keyzer-Nellen; M M Groenen-Van Dooren; J De Bruin; H Pannekoek; J A Van Mourik; M P Verbeet
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

8.  The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX.

Authors:  D J Rees; I M Jones; P A Handford; S J Walter; M P Esnouf; K J Smith; G G Brownlee
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.